Pfizer Inc. Stock

The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions --

Would you like to improve your passive income stream but don't have a lot of extra cash to throw around? If so, I have great news: These days, $100 is all it takes to acquire a share of three top

While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022

Demand for COVID-19 vaccines and drugs has been fading for a while now. And that has put a big dent in Pfizer's (NYSE: PFE) sales and profit numbers. On top of that, the stock is also facing

The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4%

Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro

Pfizer (NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of

Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021.

However, the

The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are

Just a couple of years ago, Pfizer's (NYSE: PFE) revenue was soaring thanks to sales of its coronavirus vaccine. In fact, the vaccine became the world's best-selling pharmaceutical product and even

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q2 2024 Earnings CallJul 30, 2024, 10:30 a.m. ET

Operator

Continue reading

Source Fool.com

Despite its impressive performance in 2020 and 2021, it's no secret that Pfizer (NYSE: PFE) is in the process of reinventing itself. Without much of the windfall from its coronavirus products

If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment

Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, Pfizer (NYSE: PFE) is the one Americans associate most with this

If there's one thing healthcare giant Pfizer (NYSE: PFE) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are

Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss

On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage

Few pharmaceutical companies are more prominent than Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY). However, their popularity relative to most of their peers hasn't helped them much in the

Pfizer (NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has

The past few years have been tough ones for investors holding shares of Pfizer (NYSE: PFE). The Big Pharma stock is down by more than half from the peak it set in late 2021.

Pfizer's stock price was

The benchmark S&P 500 index keeps breaking new records thanks in large part to a handful of stocks at the top. Luckily for income-seeking investors, there are some highly reliable dividend stocks

Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at

It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment

If you're an investor who doesn't already have access to billions in capital, you could probably learn a few things from the folks who do. Luckily, keeping tabs on the world's most successful

Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been steadily sliding lower over the past year as revenue and profits from the pandemic's vaccine boom dry up. Today, the stock has seemingly